Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Extended-access, but not limited-access, methamphetamine self-administration induces behavioral and nucleus accumbens dopamine response changes in rats.

Le Cozannet R, Markou A, Kuczenski R.

Eur J Neurosci. 2013 Nov;38(10):3487-95. doi: 10.1111/ejn.12361. Epub 2013 Sep 23.

2.

Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration.

Laćan G, Hadamitzky M, Kuczenski R, Melega WP.

Synapse. 2013 Aug;67(8):476-88. doi: 10.1002/syn.21654. Epub 2013 Mar 19.

3.

Development of stereotyped behaviors during prolonged escalation of methamphetamine self-administration in rats.

Hadamitzky M, McCunney S, Markou A, Kuczenski R.

Psychopharmacology (Berl). 2012 Oct;223(3):259-69. doi: 10.1007/s00213-012-2713-1. Epub 2012 Apr 20.

4.

Dielectrophoretic microfluidic device for the continuous sorting of Escherichia coli from blood cells.

Kuczenski RS, Chang HC, Revzin A.

Biomicrofluidics. 2011 Sep;5(3):32005-3200515. doi: 10.1063/1.3608135. Epub 2011 Sep 20.

5.

The metabotropic glutamate 2/3 receptor agonist LY379268 blocked nicotine-induced increases in nucleus accumbens shell dopamine only in the presence of a nicotine-associated context in rats.

D'Souza MS, Liechti ME, Ramirez-Niño AM, Kuczenski R, Markou A.

Neuropsychopharmacology. 2011 Sep;36(10):2111-24. doi: 10.1038/npp.2011.103. Epub 2011 Jun 8.

6.

Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats.

Amitai N, Kuczenski R, Behrens MM, Markou A.

Neuropharmacology. 2012 Mar;62(3):1422-31. doi: 10.1016/j.neuropharm.2011.01.008. Epub 2011 Jan 14.

7.

Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms.

Le-Niculescu H, Balaraman Y, Patel SD, Ayalew M, Gupta J, Kuczenski R, Shekhar A, Schork N, Geyer MA, Niculescu AB.

Transl Psychiatry. 2011 May 24;1:e9. doi: 10.1038/tp.2011.9.

8.

Convergent functional genomic studies of ω-3 fatty acids in stress reactivity, bipolar disorder and alcoholism.

Le-Niculescu H, Case NJ, Hulvershorn L, Patel SD, Bowker D, Gupta J, Bell R, Edenberg HJ, Tsuang MT, Kuczenski R, Geyer MA, Rodd ZA, Niculescu AB.

Transl Psychiatry. 2011 Apr 26;1:e4. doi: 10.1038/tp.2011.1.

9.

Extended access to methamphetamine self-administration affects sensorimotor gating in rats.

Hadamitzky M, Markou A, Kuczenski R.

Behav Brain Res. 2011 Mar 1;217(2):386-90. doi: 10.1016/j.bbr.2010.11.009. Epub 2010 Nov 9.

10.

Evidence for genetic association of RORB with bipolar disorder.

McGrath CL, Glatt SJ, Sklar P, Le-Niculescu H, Kuczenski R, Doyle AE, Biederman J, Mick E, Faraone SV, Niculescu AB, Tsuang MT.

BMC Psychiatry. 2009 Nov 12;9:70. doi: 10.1186/1471-244X-9-70.

11.

Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge.

Kuczenski R, Segal DS, Melega WP, Lacan G, McCunney SJ.

Neuropsychopharmacology. 2009 Oct;34(11):2430-41. doi: 10.1038/npp.2009.73. Epub 2009 Jul 1.

12.

Convergent functional genomics of genome-wide association data for bipolar disorder: comprehensive identification of candidate genes, pathways and mechanisms.

Le-Niculescu H, Patel SD, Bhat M, Kuczenski R, Faraone SV, Tsuang MT, McMahon FJ, Schork NJ, Nurnberger JI Jr, Niculescu AB 3rd.

Am J Med Genet B Neuropsychiatr Genet. 2009 Mar 5;150B(2):155-81. doi: 10.1002/ajmg.b.30887.

PMID:
19025758
13.

Potential adverse effects of amphetamine treatment on brain and behavior: a review.

Berman SM, Kuczenski R, McCracken JT, London ED.

Mol Psychiatry. 2009 Feb;14(2):123-42. doi: 10.1038/mp.2008.90. Epub 2008 Aug 12. Review. Erratum in: Mol Psychiatry. 2010 Nov;15(11):1121.

14.

Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism.

Le-Niculescu H, McFarland MJ, Ogden CA, Balaraman Y, Patel S, Tan J, Rodd ZA, Paulus M, Geyer MA, Edenberg HJ, Glatt SJ, Faraone SV, Nurnberger JI, Kuczenski R, Tsuang MT, Niculescu AB.

Am J Med Genet B Neuropsychiatr Genet. 2008 Mar 5;147B(2):134-66. doi: 10.1002/ajmg.b.30707.

PMID:
18247375
15.

PERIOD-TIMELESS interval timer may require an additional feedback loop.

Kuczenski RS, Hong KC, García-Ojalvo J, Lee KH.

PLoS Comput Biol. 2007 Aug;3(8):e154.

16.

Convergent Functional Genomics of bipolar disorder: from animal model pharmacogenomics to human genetics and biomarkers.

Le-Niculescu H, McFarland MJ, Mamidipalli S, Ogden CA, Kuczenski R, Kurian SM, Salomon DR, Tsuang MT, Nurnberger JI Jr, Niculescu AB.

Neurosci Biobehav Rev. 2007;31(6):897-903. Epub 2007 Jun 3. Review.

17.

Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat.

Kuczenski R, Everall IP, Crews L, Adame A, Grant I, Masliah E.

Exp Neurol. 2007 Sep;207(1):42-51. Epub 2007 Jun 6.

18.

Escalating dose, multiple binge methamphetamine regimen does not impair recognition memory in rats.

Clark RE, Kuczenski R, Segal DS.

Synapse. 2007 Jul;61(7):515-22.

PMID:
17415795
19.

Towards understanding the schizophrenia code: an expanded convergent functional genomics approach.

Le-Niculescu H, Balaraman Y, Patel S, Tan J, Sidhu K, Jerome RE, Edenberg HJ, Kuczenski R, Geyer MA, Nurnberger JI Jr, Faraone SV, Tsuang MT, Niculescu AB.

Am J Med Genet B Neuropsychiatr Genet. 2007 Mar 5;144B(2):129-58.

PMID:
17266109
20.

Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge.

O'Neil ML, Kuczenski R, Segal DS, Cho AK, Lacan G, Melega WP.

Synapse. 2006 Nov;60(6):465-73.

PMID:
16897726
21.

Differential regulation of immediate-early gene expression in the prefrontal cortex of rats with a high vs low behavioral response to methamphetamine.

Shilling PD, Kuczenski R, Segal DS, Barrett TB, Kelsoe JR.

Neuropsychopharmacology. 2006 Nov;31(11):2359-67. Epub 2006 Jul 19.

22.

Forebrain D1 function and sensorimotor gating in rats: effects of D1 blockade, frontal lesions and dopamine denervation.

Swerdlow NR, Shoemaker JM, Kuczenski R, Bongiovanni MJ, Neary AC, Tochen LS, Saint Marie RL.

Neurosci Lett. 2006 Jul 10;402(1-2):40-5. Epub 2006 Apr 27.

PMID:
16644125
23.

Convergent functional genomics: a Bayesian candidate gene identification approach for complex disorders.

Bertsch B, Ogden CA, Sidhu K, Le-Niculescu H, Kuczenski R, Niculescu AB.

Methods. 2005 Nov;37(3):274-9.

PMID:
16308156
24.

Improved understanding of gene expression regulation using systems biology.

Kuczenski RS, Aggarwal K, Lee KH.

Expert Rev Proteomics. 2005 Dec;2(6):915-24. Review.

PMID:
16307520
26.

Phylogenetic analysis of family 6 glycoside hydrolases.

Mertz B, Kuczenski RS, Larsen RT, Hill AD, Reilly PJ.

Biopolymers. 2005 Nov;79(4):197-206.

PMID:
16086389
27.

Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization.

Segal DS, Kuczenski R, O'Neil ML, Melega WP, Cho AK.

Psychopharmacology (Berl). 2005 Jul;180(3):501-12. Epub 2005 Mar 15.

PMID:
15959831
28.
29.

Neurochemical analysis of rat strain differences in the startle gating-disruptive effects of dopamine agonists.

Swerdlow NR, Kuczenski R, Goins JC, Crain SK, Ma LT, Bongiovanni MJ, Shoemaker JM.

Pharmacol Biochem Behav. 2005 Feb;80(2):203-11. Epub 2004 Dec 15.

PMID:
15680173
30.

Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach.

Ogden CA, Rich ME, Schork NJ, Paulus MP, Geyer MA, Lohr JB, Kuczenski R, Niculescu AB.

Mol Psychiatry. 2004 Nov;9(11):1007-29.

PMID:
15314610
31.

Altered extracellular dopamine concentration in the brains of cholecystokinin-A receptor deficient rats.

Feifel D, Shilling PD, Kuczenski R, Segal DS.

Neurosci Lett. 2003 Sep 18;348(3):147-50.

PMID:
12932815
32.
33.

Oxidative mechanisms and tardive dyskinesia.

Lohr JB, Kuczenski R, Niculescu AB.

CNS Drugs. 2003;17(1):47-62. Review.

PMID:
12467492
35.

Genetic differences in startle gating-disruptive effects of apomorphine: evidence for central mediation.

Swerdlow NR, Shoemaker JM, Pitcher L, Platten A, Kuczenski R, Eleey CC, Auerbach P.

Behav Neurosci. 2002 Aug;116(4):682-90.

PMID:
12148935
36.
37.
38.

Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse.

Cho AK, Melega WP, Kuczenski R, Segal DS.

Synapse. 2001 Feb;39(2):161-6. Review.

PMID:
11180503
39.

Identifying a series of candidate genes for mania and psychosis: a convergent functional genomics approach.

Niculescu AB 3rd, Segal DS, Kuczenski R, Barrett T, Hauger RL, Kelsoe JR.

Physiol Genomics. 2000 Nov 9;4(1):83-91.

PMID:
11074017
40.

In vivo microdialysis assessment of extracellular serotonin and dopamine levels in awake monkeys during sustained fluoxetine administration.

Smith TD, Kuczenski R, George-Friedman K, Malley JD, Foote SL.

Synapse. 2000 Dec 15;38(4):460-70.

PMID:
11044893
41.

Differential regional zif268 messenger RNA expression in an escalating dose/binge model of amphetamine-induced psychosis.

Shilling PD, Kelsoe JR, Kuczenski R, Segal DS.

Neuroscience. 2000;96(1):83-90.

PMID:
10683413
42.

Dynamic changes in sensitivity occur during the acute response to cocaine and methylphenidate.

Kuczenski R, Segal DS.

Psychopharmacology (Berl). 1999 Nov;147(1):96-103.

PMID:
10591874
43.

Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile.

Segal DS, Kuczenski R.

J Pharmacol Exp Ther. 1999 Oct;291(1):19-30.

PMID:
10490882
45.
46.

Caudate-putamen dopamine and stereotypy response profiles after intravenous and subcutaneous amphetamine.

Cho AK, Melega WP, Kuczenski R, Segal DS, Schmitz DA.

Synapse. 1999 Feb;31(2):125-33.

PMID:
10024009
47.

l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine.

Melega WP, Cho AK, Schmitz D, Kuczenski R, Segal DS.

J Pharmacol Exp Ther. 1999 Feb;288(2):752-8.

PMID:
9918585
48.

Sensitization of amphetamine-induced stereotyped behaviors during the acute response.

Kuczenski R, Segal DS.

J Pharmacol Exp Ther. 1999 Feb;288(2):699-709.

PMID:
9918578
49.

Behavioral sensitization and extracellular dopamine responses to amphetamine after various treatments.

Kuczenski R, Segal DS, Todd PK.

Psychopharmacology (Berl). 1997 Dec;134(3):221-9.

PMID:
9438672
50.

Behavioral alterations induced by an escalating dose-binge pattern of cocaine administration.

Segal DS, Kuczenski R.

Behav Brain Res. 1997 Nov;88(2):251-60.

PMID:
9404634

Supplemental Content

Loading ...
Support Center